Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group. Trenkwalder C, et al. Among authors: valis m. Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19. Lancet Neurol. 2015. PMID: 26494524 Clinical Trial.
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. Kappos L, et al. Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10. Neurology. 2016. PMID: 27511182 Free PMC article. Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
Corvol JC, Azulay JP, Bosse B, Dauvilliers Y, Defebvre L, Klostermann F, Kovacs N, Maltête D, Ondo WG, Pahwa R, Rein W, Thobois S, Valis M, Videnovic A, Rascol O; THN102-202 Study Investigators. Corvol JC, et al. Among authors: valis m. Mov Disord. 2022 Feb;37(2):410-415. doi: 10.1002/mds.28840. Epub 2021 Oct 28. Mov Disord. 2022. PMID: 34709684 Clinical Trial.
Tourette Syndrome: A Mini-Review.
Novotny M, Valis M, Klimova B. Novotny M, et al. Among authors: valis m. Front Neurol. 2018 Mar 9;9:139. doi: 10.3389/fneur.2018.00139. eCollection 2018. Front Neurol. 2018. PMID: 29593638 Free PMC article. Review.
PPI Long Term Use: Risk of Neurological Adverse Events?
Novotny M, Klimova B, Valis M. Novotny M, et al. Among authors: valis m. Front Neurol. 2019 Jan 8;9:1142. doi: 10.3389/fneur.2018.01142. eCollection 2018. Front Neurol. 2019. PMID: 30671013 Free PMC article. Review.
197 results